Streetbeat News

Analyst Ratings

KALV

Jones Trading has initiated coverage on KalVista Pharma with a Buy rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:39 pm

ACN

RBC Capital analyst Daniel Perlin has maintained an 'Outperform' rating on Accenture (NYSE:ACN) and raised the price target from $377 to $389.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:38 pm

KMX

RBC Capital analyst Steven Shemesh has maintained an 'Outperform' rating on CarMax (NYSE:KMX) and raised the price target from $75 to $82.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:36 pm

VFC

Jefferies has initiated coverage on VF Corporation (NYSE:VFC) with a Hold rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:34 pm

ITRI

Janney Montgomery Scott has initiated coverage on Itron (NASDAQ:ITRI) with a Buy rating and set a price target of $131.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:30 pm

CPB

DA Davidson has downgraded Campbell Soup (NASDAQ:CPB) from Buy to Neutral, setting a price target of $51.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:27 pm

LEGN

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating for Legend Biotech (NASDAQ:LEGN) and maintained a price target of $86.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:27 pm

ADSK

DA Davidson has initiated coverage on Autodesk with a Neutral rating and set a price target of $260.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:26 pm

BB

RBC Capital analyst Paul Treiber has reiterated a Sector Perform rating on BlackBerry and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:17 pm

BVS

Craig-Hallum analyst Alexander Nowak maintains a Buy rating on Bioventus (NASDAQ:BVS) and raises the price target from $12 to $17.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:15 pm